Table 1: Adverse events of CGRP monoclonal antibodies compared to placebo.

Patients with AE/patients treated with CGRP drugs; patients with AE/ treated with placebo
AEs	No	Eptinezumab	Placebo	Galcanezumab	Placebo	Erenumab	Placebo	Fremanezumab	Placebo	RR (95% CI)	P and I^2
Any AE	6	46/81	43/82	77/107	74/110	658/1235^*	441/761	385/581	171/293	0.99 [0.90, 1010]	P = 0.90, I^2 = 59%^a
Upper respiratory tract infection	10	7/81	6/82	81/1202	50/1080	60/1235	35/761	33/773	19/397	1.17 [0.93, 1.47]	P = 0.18, I^2 = 0%
Nausea	9	3/81	2/82	24/806	29/679	27/1235	21/761	12/773	9/397	0.79 [0.55, 1.12]	P = 0.19, I^2 = 0%
Nasopharyngitis	9	NR	NR	80/1260	79/1140	102/1235	61/761	26/773	11/397	0.97 [0.79, 1.20]	P = 0.79, I^2 = 0%
Injection site pain	8	NR	NR	168/1260	125/1140	28/916	13/608	186/773	82/397	1.32 [1.02, 1.71]	P = 0.03, I^2 = 44%^a,b
Sinusitis	7	NR	NR	27/806	21/679	24/916	13/608	11/773	11/397	0.99 [0.67, 1.44]	P = 0.94, I^2 = 0%
Dizziness	5	3/81	1/82	31/987	24/1003	NR	NR	6/192	0/104	1.53 [0.93, 2.51]	P = 0.10, I^2 = 0%
Back pain	7	3/81	4/82	29/806	17/679	19/952	11/472	4/192	2/104	1.13 [0.74, 1.73]	P = 0.57, I^2 = 0%
Fatigue	7	3/81	3/82	11/454	12/461	34/1235	17/761	13/773	5/397	1.16 [0.77, 1.75]	P = 0.47, I^2 = 0%
Influenza	5	NR	NR	22/880	19/893	23/916	16/608	3/192	1/104	1.14 [0.74, 1.76]	P = 0.55, I^2 = 0%
Urinary tract infection	6	1/81	4/82	21/426	15/432	13/916	7/608	20/773	7/397	1.19 [0.78, 1.83]	P = 0.42, I^2 = 3%
Migraine	6	1/81	2/82	7/426	4/432	20/1235	20/761	2/192	2/104	0.76 [0.46, 1.27]	P = 0.29, I^2 = 10%
Arthralgia	5	1/81	4/82	7/107	6/110	16/952	11/472	3/192	0/104	0.84 [0.48, 1.48]	P = 0.55, I^2 = 36%
Injection site erythema	6	NR	NR	38/1260	15/1140	NR	NR	114/773	44/397	1.55 [1.17, 2.05]	P = 0.00, I^2 = 0%^b

AEs: adverse events; No: the number of studies included in the quantitative analysis; NR: not reported.
^aAnalysis was performed with random effect size model.
^bResults were significant.